Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.3.0.814
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
[1]
Current assets:    
Cash and cash equivalents $ 212,144 $ 96,907
Accounts receivable, net 189,725 19,969
Inventory, net 40,693 16,604
Prepaid expenses and other current assets 74,854 9,389
Total current assets 517,416 142,869
Property, plant and equipment, net 126,822 16,411
Intangible assets, net 660,287 62,649
In-process research and development 812,723 793,152
Goodwill 761,234 224,292
Investments, net 34,695 22,453
Other assets, principally deferred tax assets 102,676 5,838
Total assets 3,015,853 1,267,664
Current liabilities:    
Accounts payable 77,969 8,744
Accrued expenses 201,113 60,912
Current portion of lines of credit and notes payable 78,508 13,455
Total current liabilities 357,590 83,111
2033 Senior Notes, net of discount and estimated fair value of embedded derivatives 44,206 131,454
Deferred tax liabilities 408,213 167,153
Other long-term liabilities, principally deferred revenue and contingent consideration 236,476 50,205
Total long-term liabilities 688,895 348,812
Total liabilities 1,046,485 431,923
Equity:    
Common Stock - $0.01 par value, 750,000,000 shares authorized; 545,951,707 and 433,421,677 shares issued at September 30, 2015 and December 31, 2014, respectively 5,459 4,334
Treasury Stock - 1,120,367 and 1,245,367 shares at September 30, 2015 and December 31, 2014, respectively (3,645) (4,051)
Additional paid-in capital 2,696,420 1,529,096
Accumulated other comprehensive income (loss) (20,992) (12,392)
Accumulated deficit (706,474) (674,843)
Total shareholders’ equity attributable to OPKO 1,970,768 842,144
Noncontrolling interests (1,400) (6,403)
Total shareholders’ equity 1,969,368 835,741
Total liabilities and equity $ 3,015,853 $ 1,267,664
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 5. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.